



(11) **EP 0 879 596 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:

**Corrected version no 1 (W1 B1)**  
**INID code(s) 72,73**

(51) Int Cl.:

**A61K 31/14** <sup>(2006.01)</sup> **A61K 31/405** <sup>(2006.01)</sup>  
**A61K 31/435** <sup>(2006.01)</sup> **A61K 31/44** <sup>(2006.01)</sup>  
**A61K 31/66** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**23.05.2007 Bulletin 2007/21**

(45) Date of publication and mention  
of the grant of the patent:

**16.08.2006 Bulletin 2006/33**

(21) Application number: **98201818.6**

(22) Date of filing: **14.05.1992**

(54) **Use of galanthamines to reduce benzodiazepine side effects**

Verwendung von Galanthaminen zur Linderung von Benzodiazepin-Nebenwirkungen

Utilisation de galanthamines contre les effets secondaires des benzodiazepines

(84) Designated Contracting States:

**AT BE CH DE DK ES FR GB GR IT LI LU MC NL  
PT SE**

(30) Priority: **14.05.1991 IS 370691**

**31.07.1991 IS 370691**

**13.02.1992 DK 18292**

(43) Date of publication of application:

**25.11.1998 Bulletin 1998/48**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:

**92917377.1 / 0 584 285**

(73) Proprietor: **Snorrason, Ernir**

**105 Reykjavik (IS)**

(72) Inventor: **Snorrason, Ernir**

**105 Reykjavik (IS)**

(74) Representative: **Fairbairn, Angus Chisholm**

**Marks & Clerk**

**90 Long Acre**

**London WC2E 9RA (GB)**

(56) References cited:

- **G. FOSTER LARSON ET AL.:** "Physostigmine reversal of diazepam-induced depression." **ANESTH. ANALG.**, vol. 56, no. 3, 1977, pages 348-352, XP002075350
- **E. VATASHSKY ET AL.:** "Mechanism of antagonism by physostigmine of acute flunitrazepam intoxication." **ANESTESIOLOG.**, vol. 64, no. 2, 1986, pages 248-252, XP002075351
- **C.D. BLITT ET AL.:** "Reversal of lorazepam delirium by physostigmine." **ANESTH. ANALG.**, vol. 54, no. 5, 1975, pages 607-608, XP002075352
- **P.M.P. LAUVEN ET AL.:** "Flumazenil (Ro 15-1788) and physostigmine." **RESUSCITATION**, vol. 16, no. suppl., 1988, pages S41-S48, XP002075353
- **W.E. HOFFMAN ET AL.:** "Cerebrovascular and cerebral metabolic effects of physostigmine, midazolam, and a benzodiazepine antagonist." **ANESTH. ANALG.**, vol. 65, no. 6, 1986, pages 639-644, XP002075354
- **U.A. PANDIT ET AL.:** "Physostigmine fails to reverse clinical, psychomotor, or EEG effects of lorazepam." **ANESTH. ANALG.**, vol. 62, no. 7, 1983, pages 679-685, XP002075355

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 879 596 B8**